Ignite Creation Date:
2024-07-17 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06471803
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-06-18
Brief Title:
Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease
Sponsor:
Henan Province Clinical Research Center for Cardiovascular Diseases
Organization:
Henan Province Clinical Research Center for Cardiovascular Diseases
Study Overview
Official Title:
Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease and Related Mechanism Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASCVD-MOMENT
Brief Summary:
The current biological issues driving the evolutionary progression of coronary artery disease are in focus at this stage the biological evidence for them is scarce and small in scale with the exception of metabolomics and microbiomics Issues such as histologic mapping of coronary atherosclerosis deterioration remain to be corroborated by more clinical and basic evidence By analyzing the clinical data and multi-omics data of patients with coronary heart disease investigators will explore the related risk factors and establish molecular subtypes and prognostic prediction models for individualized prediction of coronary heart disease risk in order to guide the clinical screening of high-risk groups of coronary heart disease and formulate more targeted intervention countermeasures
Detailed Description:
The biological mechanisms driving the progression of coronary artery disease CAD are complex and multifaceted While there have been significant advances in understanding these mechanisms much of the biological evidence remains limited and fragmented especially beyond the realms of metabolomics and microbiomics For instance the detailed histologic mapping of the deterioration of coronary atherosclerosis still requires more extensive clinical and basic research to substantiate initial findings
To address these gaps researchers are turning to comprehensive analyses of clinical and multi-omics data from patients with coronary heart disease This involves a deep dive into various data types including genomics proteomics metabolomics and microbiomics to identify potential risk factors associated with CAD By integrating these data investigators aim to uncover molecular subtypes of the disease that can provide a more nuanced understanding of its progression
Furthermore the goal is to develop robust prognostic prediction models that can accurately forecast the risk of CAD in individual patients These models will leverage the identified molecular subtypes and associated risk factors to offer personalized predictions which are crucial for effective clinical decision-making Through this individualized approach it will be possible to enhance the screening processes for high-risk groups and design more precise and effective intervention strategies
Ultimately this research endeavors to bridge the gap between basic scientific discoveries and clinical applications paving the way for tailored therapeutic interventions that can significantly improve patient outcomes in coronary artery disease
To address these gaps researchers are turning to comprehensive analyses of clinical and multi-omics data from patients with coronary heart disease This involves a deep dive into various data types including genomics proteomics metabolomics and microbiomics to identify potential risk factors associated with CAD By integrating these data investigators aim to uncover molecular subtypes of the disease that can provide a more nuanced understanding of its progression
Furthermore the goal is to develop robust prognostic prediction models that can accurately forecast the risk of CAD in individual patients These models will leverage the identified molecular subtypes and associated risk factors to offer personalized predictions which are crucial for effective clinical decision-making Through this individualized approach it will be possible to enhance the screening processes for high-risk groups and design more precise and effective intervention strategies
Ultimately this research endeavors to bridge the gap between basic scientific discoveries and clinical applications paving the way for tailored therapeutic interventions that can significantly improve patient outcomes in coronary artery disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None